Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 552 KB, PDF-dokument
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Leukemia |
| Vol/bind | 37 |
| Udgave nummer | 10 |
| Sider (fra-til) | 2129-2132 |
| Antal sider | 4 |
| ISSN | 0887-6924 |
| DOI |
|
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This study was supported by research funding from AOP Health. Special thanks to the patients and their families, to study support staff. Statement of prior presentation: Presented in part in abstract form at Congresses of the European Hematology Association, 9–17 June 2022 and 8–11 June 2023.
ID: 370578149